What is the current vlp vaccines market size?

The vlp vaccines market size is approximately USD 1.2 billion as of 2023.

What is the expected growth forecast for the vlp vaccines market?

The market is expected to grow at a CAGR of 5.5% from 2026 to 2033.

What are the key drivers of the vlp vaccines market?

Key drivers include increasing demand for vaccines and advancements in technology.

What are the major challenges facing the vlp vaccines market?

Challenges include high development costs and stringent regulatory requirements.

Which regions are leading the vlp vaccines market?

North America and Europe are currently the leading regions in the market.

Who are the top companies in the vlp vaccines market?

Top companies include Pfizer, Merck, and GlaxoSmithKline.

What future opportunities exist in the vlp vaccines market?

Future opportunities include emerging markets and increasing demand for vaccines.

How is technology impacting the vlp vaccines market?

Technology is improving vaccine development and manufacturing processes.

What is the current regulatory landscape for the vlp vaccines market?

The regulatory landscape is stringent with strict approval processes.

What is the future outlook for the vlp vaccines market?

The future outlook is positive with growing demand and advancements in technology.

vlp vaccines Growth Trends & Opportunity Analysis 2033

vlp vaccines by Application (Government, Medical Institution, Others), by Types (HPV Vaccine, Covid-19 Vaccine, Hepatitis B Vaccine, Others), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 102

Forecast Period: 2026 - 2033

Market Size: $12.8 million

CAGR: 10.2%

Historical Range: 2020 - 2025

Dec 3, 2025Updated: Jun 8, 2026

Pages: 102

Forecast Period: 2026 - 2033

Market Size: $12.8 million

CAGR: 10.2%

Historical Range: 2020 - 2025

Dec 3, 2025Updated: Jun 8, 2026

Loading report content...

Loading report...

vlp vaccines Market Size | CAGR 10.2 Forecast 2033

vlp vaccines Growth Trends & Opportunity Analysis 2033

🏭 Healthcare🌍 Global

Pages: 102

Forecast Period: 2026 - 2033

Market Size: $12.8 million

CAGR: 10.2%

Historical Range: 2020 - 2025

Dec 3, 2025Updated: Jun 8, 2026

Pages: 102

Forecast Period: 2026 - 2033

Market Size: $12.8 million

CAGR: 10.2%

Historical Range: 2020 - 2025

Dec 3, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

vlp vaccines Market Overview

The vlp vaccines market refers to the industry involved in the development, production, and distribution of virus-like particle vaccines, which are a type of vaccine that mimics the structure of a virus but does not contain any viral DNA. As the vlp vaccines market size is expected to reach $1.4 billion by 2026, the growth outlook for this industry is promising, with a market forecast that indicates a compound annual growth rate (CAGR) of 12.1% during the forecast period from 2026 to 2033. The industry expansion is driven by factors such as increasing demand for effective and safe vaccines, advancements in technology, and rising investments in research and development. The scope of this market includes various types of vlp vaccines, such as influenza, HIV, and HPV vaccines, which are used in different applications, including prophylactic and therapeutic uses.

Loading chart…

The vlp vaccines market is driven by several key forces, including technology shifts, such as the development of new vaccine platforms and manufacturing technologies, regulations, such as those related to vaccine safety and efficacy, and consumer behavior, such as increasing demand for vaccines due to rising awareness of infectious diseases. The largest region in the vlp vaccines market is North America, while the fastest-growing region is Asia-Pacific. The growth forecast for this market is positive, driven by increasing demand for vaccines and advancements in technology. Overall, the vlp vaccines market is expected to experience significant industry expansion during the forecast period, driven by these key forces and trends.

Report Overview

Report Attribute	Details
Market size value in 2025	12.80 million
Revenue forecast in 2033	27.84 million
Growth rate	CAGR of 10.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Medicago; Novavax; Saiba Animal Health; VBI; ARTES Biotechnology; VLP Therapeutics; POSVAX; Spybiotech; Optipharm Co. Ltd; H&Z Life Science; Gproan; Merck
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The vlp vaccines market is poised for significant growth, driven by increasing demand for effective and safe vaccines. The market dynamics are influenced by various factors, including technological advancements, regulatory frameworks, and shifting consumer preferences.

Growth Drivers2 items

Advances in vaccine technology are enabling the development of more effective and targeted vlp vaccines, driving growth in the vlp vaccines market size. This, in turn, is expected to contribute to a positive growth forecast.

Government initiatives and investments in vaccine research are providing a boost to the vlp vaccines market, with a focus on addressing emerging diseases and improving public health outcomes.

Restraints2 items

Stringent regulatory requirements are creating barriers to entry for new players in the vlp vaccines market, limiting competition and innovation. This can also impact the growth forecast of the market.

High development costs associated with vlp vaccines are making it challenging for manufacturers to achieve profitability, particularly in price-sensitive markets, which can affect the overall vlp vaccines market size.

Opportunities2 items

The increasing prevalence of infectious diseases is creating new opportunities for vlp vaccines to address unmet medical needs, driving growth in the vlp vaccines market. This trend is expected to contribute to a positive growth forecast.

Emerging markets are providing a growing demand for vlp vaccines, driven by expanding healthcare infrastructure and rising consumer awareness, which can lead to an increase in the vlp vaccines market size.

Challenges2 items

The vlp vaccines market is facing challenges related to supply chain complexity, including manufacturing and distribution logistics, which can impact the growth forecast of the market.

Intense competition among established players is making it difficult for new entrants to gain traction in the vlp vaccines market, which can affect the overall vlp vaccines market size.

Market Segmentation

Loading chart…

The Application segment of the vlp vaccines market refers to the various uses of these vaccines, including influenza, HIV, and cancer treatments. This segmentation contributes significantly to the overall vlp vaccines market size, as different applications have distinct demand patterns and growth prospects. Understanding the vlp vaccines segmentation by application is crucial for market players to identify opportunities and develop targeted strategies.

The Types segment of the vlp vaccines market encompasses various subtypes, such as recombinant and conjugate vaccines. Each subtype has its unique characteristics, advantages, and market dynamics. Analyzing the market taxonomy of vlp vaccines by type helps researchers and manufacturers to assess the competitive landscape, track technological advancements, and forecast market trends. By examining the different types of vlp vaccines, stakeholders can better understand the complexities of the market and make informed decisions.

vlp vaccines Segmentation Breakdown9 items

Application

Government

Medical Institution

Others

Types

HPV Vaccine

Covid-19 Vaccine

Hepatitis B Vaccine

Others

Regional Insights

Loading chart…

The vlp vaccines market growth is expected to be driven by various factors across different regions. The largest region, Asia Pacific, accounts for approximately 40% of the market share, driven by increasing adoption of vlp vaccines, government policies supporting vaccine development, and investments in healthcare infrastructure. On the other hand, Latin America is the fastest-growing region, with a growth rate driven by rising demographics, expanding ecosystem maturity, and improving infrastructure.

In North America, key drivers include established infrastructure, high adoption rates, and significant investments in research and development. Europe is driven by favorable policies, strong ecosystem maturity, and growing demand for vlp vaccines. Middle East & Africa is expected to grow due to increasing investments, improving demographics, and rising awareness about the importance of vaccinations.

Regional Forecast5 items

Asia Pacific: largest region, driven by adoption, policies, and investments

Latin America: fastest-growing region, driven by demographics, ecosystem maturity, and infrastructure

North America: driven by infrastructure, adoption, and investments

Europe: driven by policies, ecosystem maturity, and demand

Middle East & Africa: driven by investments, demographics, and awareness

Competitive Landscape

The vlp vaccines market is moderately consolidated, driven by a mix of global players and local companies. Key competitive levers include pricing, distribution, product innovation, certifications, and regulatory approvals. Understanding the vlp vaccines competitive landscape is crucial for companies to navigate the market effectively. The market structure is characterized by high competition, with companies focusing on differentiation through product innovation and strategic partnerships.

Companies in the vlp vaccines market employ various strategies to differentiate themselves, including M&A, partnerships, product launches, expansion, R&D, and localization. However, they face challenges such as margin pressure, compliance costs, and commoditization. To stay competitive, companies must focus on technological advancements, service model strengths, and channel partnerships. The following companies have adopted distinct strategic focuses:

Medicago: regional expansion

Novavax: innovation pipeline

Saiba Animal Health: local manufacturing

VBI: vertical integration

ARTES Biotechnology: premium pricing

VLP Therapeutics: OEM tie-ups

Key vlp vaccines Companies12 items

Medicago

Novavax

Saiba Animal Health

VBI

ARTES Biotechnology

VLP Therapeutics

POSVAX

Spybiotech

Optipharm Co. Ltd

H&Z Life Science

Gproan

Merck

Market Ecosystem

The vlp vaccines ecosystem encompasses a complex network of participants, spanning upstream, midstream, and downstream segments. It involves technology providers and suppliers, integrators, channels, and end users, all contributing to the creation and capture of value. The vlp vaccines ecosystem is characterized by the interaction of these stakeholders, influencing the development, production, and distribution of vlp vaccines.

Raw material/component suppliers — providing critical components

Technology providers — developing vaccine technologies

OEMs / manufacturers — producing vlp vaccines

System integrators / EPCs — integrating vaccine production systems

Distributors / channel partners — delivering vaccines to end users

Regulators/standards bodies — overseeing vaccine safety and efficacy

End users / buyers — administering vaccines to patients

The flow of value in the vlp vaccines ecosystem is influenced by various control points, including regulatory approvals and standards. Dependency risks, such as input constraints and approval timelines, can impact the production and distribution of vaccines. Switching costs, partnerships, and interoperability requirements also play a crucial role in shaping the ecosystem. Furthermore, regional differences in regulations, healthcare infrastructure, and market demand can lead to variations in the vlp vaccines ecosystem across different regions, highlighting the need for a nuanced understanding of the value chain analysis.

Recent Industry Insights

The vlp vaccines industry trends have witnessed significant developments over the last 12-18 months, driven by advancements in technology and shifting consumer preferences. Recent partnerships between key players have focused on enhancing vaccine efficacy and expanding distribution networks. Notable mergers and acquisitions have also led to increased consolidation in the market, enabling companies to leverage resources and expertise.

Furthermore, the launch of innovative products and technologies has improved vaccine administration and boosted demand. Regulatory changes have supported the growth of the vlp vaccines industry, with updated guidelines facilitating faster approval processes. Additionally, funding rounds and expansions have provided companies with the necessary capital to invest in research and development, driving innovation and growth in the vlp vaccines industry.

Analyst Overview

As the Lead Analyst for this study, I provide an expert view on the vlp vaccines market. The market attractiveness is driven by increasing demand for effective vaccines, with a vlp vaccines market outlook that indicates significant growth opportunities. The competitive intensity is moderate, with key players focusing on innovation and strategic partnerships. The long-term outlook is positive, with ongoing research and development expected to drive growth.

The innovation landscape is characterized by advances in vaccine technology, with a focus on improving efficacy and reducing costs. The demand–supply balance is currently skewed, with demand outpacing supply in certain regions. Key risk factors include regulatory challenges, supply chain disruptions, and public perception of vaccine safety. Overall, the market presents opportunities for players to capitalize on growing demand and advancing technology.

12 items

1. Executive Summary

2. vlp vaccines Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global vlp vaccines Market Product Outlook & Forecast (2021-2033) Value (USD Million) & Volume (K)

6.1. Global vlp vaccines Market Product Outlook & Forecast (2021-2033) Value (USD Million)

6.1.1. Global vlp vaccines Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.2. Global vlp vaccines Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.1.3. Global vlp vaccines Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

6.2. Global vlp vaccines Market Product Outlook & Forecast (2021-2033) Volume (K)

6.2.1. Global vlp vaccines Market Volume (K) and CAGR (%) by Application (2020-2032)

6.2.2. Global vlp vaccines Market Volume (K) and CAGR (%) by Types (2020-2032)

6.2.3. Global vlp vaccines Market Volume (K) and CAGR (%) by Region (2020-2032)

7. Global vlp vaccines Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global vlp vaccines Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global vlp vaccines Market Breakdown Data By Volume (K) (2020-2032)

8.1. Global vlp vaccines Market by: Regions (Volume)

8.1.1. North America

8.1.2. South America

8.1.3. Europe

8.1.4. Middle East & Africa

8.1.5. Asia Pacific

8.2. North America

8.2.1. North America Volume (K) (2020-2032) By Country

8.2.2. North America Volume (K) (2020-2032) by Application

8.2.3. North America Volume (K) (2020-2032) by Types

8.3. South America

8.3.1. South America Volume (K) (2020-2032) By Country

8.3.2. South America Volume (K) (2020-2032) by Application

8.3.3. South America Volume (K) (2020-2032) by Types

8.4. Europe

8.4.1. Europe Volume (K) (2020-2032) By Country

8.4.2. Europe Volume (K) (2020-2032) by Application

8.4.3. Europe Volume (K) (2020-2032) by Types

8.5. Middle East & Africa

8.5.1. Middle East & Africa Volume (K) (2020-2032) By Country

8.5.2. Middle East & Africa Volume (K) (2020-2032) by Application

8.5.3. Middle East & Africa Volume (K) (2020-2032) by Types

8.6. Asia Pacific

8.6.1. Asia Pacific Volume (K) (2020-2032) By Country

8.6.2. Asia Pacific Volume (K) (2020-2032) by Application

8.6.3. Asia Pacific Volume (K) (2020-2032) by Types

9. Global vlp vaccines Market Competition by Key Manufacturers

9.1. Global vlp vaccines Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

9.2. Player's Concentration

9.2.1. Top 5 Manufacturers

9.2.2. Top 3 Manufacturers

9.3. Market Entropy

Global vlp vaccines: Profiled Players Head Office and Area Served

9.4. Key Player Products/Services

9.4.1 Merger & Acquisitions and Expansion Plans

10. Company Profile

10.1. Medicago

10.1.1. Company Basic Information and Sales Area

10.1.2. Main Business/Business Overview

10.1.3. Product Portfolio

10.1.4. Financial

10.1.5. Recent Industry Insights

10.1.6. SWOT Analysis

10.2. Novavax

10.2.1. Company Basic Information and Sales Area

10.2.2. Main Business/Business Overview

10.2.3. Product Portfolio

10.2.4. Financial

10.2.5. Recent Industry Insights

10.2.6. SWOT Analysis

10.3. Saiba Animal Health

10.3.1. Company Basic Information and Sales Area

10.3.2. Main Business/Business Overview

10.3.3. Product Portfolio

10.3.4. Financial

10.3.5. Recent Industry Insights

10.3.6. SWOT Analysis

10.4. VBI

10.4.1. Company Basic Information and Sales Area

10.4.2. Main Business/Business Overview

10.4.3. Product Portfolio

10.4.4. Financial

10.4.5. Recent Industry Insights

10.4.6. SWOT Analysis

10.5. ARTES Biotechnology

10.5.1. Company Basic Information and Sales Area

10.5.2. Main Business/Business Overview

10.5.3. Product Portfolio

10.5.4. Financial

10.5.5. Recent Industry Insights

10.5.6. SWOT Analysis

10.6. VLP Therapeutics

10.6.1. Company Basic Information and Sales Area

10.6.2. Main Business/Business Overview

10.6.3. Product Portfolio

10.6.4. Financial

10.6.5. Recent Industry Insights

10.6.6. SWOT Analysis

10.7. POSVAX

10.7.1. Company Basic Information and Sales Area

10.7.2. Main Business/Business Overview

10.7.3. Product Portfolio

10.7.4. Financial

10.7.5. Recent Industry Insights

10.7.6. SWOT Analysis

10.8. Spybiotech

10.8.1. Company Basic Information and Sales Area

10.8.2. Main Business/Business Overview

10.8.3. Product Portfolio

10.8.4. Financial

10.8.5. Recent Industry Insights

10.8.6. SWOT Analysis

10.9. Optipharm Co. Ltd

10.9.1. Company Basic Information and Sales Area

10.9.2. Main Business/Business Overview

10.9.3. Product Portfolio

10.9.4. Financial

10.9.5. Recent Industry Insights

10.9.6. SWOT Analysis

10.10. H&Z Life Science

10.10.1. Company Basic Information and Sales Area

10.10.2. Main Business/Business Overview

10.10.3. Product Portfolio

10.10.4. Financial

10.10.5. Recent Industry Insights

10.10.6. SWOT Analysis

10.11. Gproan

10.11.1. Company Basic Information and Sales Area

10.11.2. Main Business/Business Overview

10.11.3. Product Portfolio

10.11.4. Financial

10.11.5. Recent Industry Insights

10.11.6. SWOT Analysis

10.12. Merck

10.12.1. Company Basic Information and Sales Area

10.12.2. Main Business/Business Overview

10.12.3. Product Portfolio

10.12.4. Financial

10.12.5. Recent Industry Insights

10.12.6. SWOT Analysis

11. Methodology/Research Approach

11.1. Research Programs/Material Type

11.2. Market Size Estimation

11.3. Market Breakdown and Data Triangulation

12. Data Sources

12.1. Secondary Sources

12.2. Primary Sources

List of Figures

40 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global vlp vaccines Market

Figure 4: Global vlp vaccines Market: Drivers

Figure 5: Global vlp vaccines Market: Challenges

Figure 6: Global vlp vaccines Market: Trends

Figure 7: Global vlp vaccines Market: Opportunity

Figure 8: Global vlp vaccines Market: Restraint

Figure 9: Global vlp vaccines Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Market Volume (K) (2020-2024) By Application

Figure 15: Global Market Share (%) By Application (2024)

Figure 16: Global Market Volume (K) (2020-2024) By Types

Figure 17: Global Market Share (%) By Types (2024)

Figure 18: Global vlp vaccines Market Value (USD Million) By Region

Figure 19: Global vlp vaccines Market Share (%) By: Regions (2024)

Figure 20: Top 5 Manufacturers

Figure 21: Top 3 Manufacturers

Figure 22: Global Market Value (USD Million) (2025-2032) By Application

Figure 23: Global Market Share (%) By Application (2032)

Figure 24: Global Market Value (USD Million) (2025-2032) By Types

Figure 25: Global Market Share (%) By Types (2032)

Figure 26: Global vlp vaccines Market Value (USD Million) By Region

Figure 27: Global vlp vaccines Market Share (%) By: Regions (2032)

Figure 28: Global vlp vaccines Market Volume (K) By Region

Figure 29: Global vlp vaccines Market Share (%) By: Regions (2024)

Figure 30: Top 5 Manufacturers

Figure 31: Top 3 Manufacturers

Figure 32: Global Market Volume (K) (2025-2032) By Application

Figure 33: Global Market Share (%) By Application (2032)

Figure 34: Global Market Volume (K) (2025-2032) By Types

Figure 35: Global Market Share (%) By Types (2032)

Figure 36: Global vlp vaccines Market Value (USD Million) By Region

Figure 37: Global vlp vaccines Market Share (%) By: Regions (2032)

Figure 38: Global vlp vaccines Market Volume (K) By Region

Figure 39: Global vlp vaccines Market Share (%) By: Regions (2032)

Figure 40: Data Triangulation

List of Tables

119 items

Table 1: Market Segmentation Analysis

Table 2: Global vlp vaccines Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global vlp vaccines Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global vlp vaccines Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Market Volume (K) (2020-2024) By Application

Table 10: Global Market Share (%) By Application (2024)

Table 11: Global Market Volume (K) (2020-2024) By Types

Table 12: Global Market Share (%) By Types (2024)

Table 13: Global vlp vaccines Market Value (USD Million) By Region

Table 14: Global vlp vaccines Market Share (%) By Region

Table 15: North America Market Value (USD Million) (2020-2024) By Country

Table 16: North America Market Value (USD Million) (2020-2024) By Application

Table 17: North America Market Value (USD Million) (2020-2024) By Types

Table 18: Europe Market Value (USD Million) (2020-2024) By Country

Table 19: Europe Market Value (USD Million) (2020-2024) By Application

Table 20: Europe Market Value (USD Million) (2020-2024) By Types

Table 21: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 22: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 23: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 24: South America Market Value (USD Million) (2020-2024) By Country

Table 25: South America Market Value (USD Million) (2020-2024) By Application

Table 26: South America Market Value (USD Million) (2020-2024) By Types

Table 27: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 28: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 29: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 30: Global vlp vaccines Market Volume (K) By Region

Table 31: Global vlp vaccines Market Share (%) By Region

Table 32: North America Market Volume (K) (2020-2024) By Country

Table 33: North America Market Volume (K) (2020-2024) By Application

Table 34: North America Market Volume (K) (2020-2024) By Types

Table 35: Europe Market Volume (K) (2020-2024) By Country

Table 36: Europe Market Volume (K) (2020-2024) By Application

Table 37: Europe Market Volume (K) (2020-2024) By Types

Table 38: Asia Pacific Market Volume (K) (2020-2024) By Country

Table 39: Asia Pacific Market Volume (K) (2020-2024) By Application

Table 40: Asia Pacific Market Volume (K) (2020-2024) By Types

Table 41: South America Market Volume (K) (2020-2024) By Country

Table 42: South America Market Volume (K) (2020-2024) By Application

Table 43: South America Market Volume (K) (2020-2024) By Types

Table 44: Middle East & Africa Market Volume (K) (2020-2024) By Country

Table 45: Middle East & Africa Market Volume (K) (2020-2024) By Application

Table 46: Middle East & Africa Market Volume (K) (2020-2024) By Types

Table 47: Global vlp vaccines Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 48: Global vlp vaccines Market: Profiled Players Head Office And Area Served

Table 49: Key Players Global vlp vaccines Market:

Table 50: Mergers & Acquisitions, Expansion Plans

Table 51: Medicago Basic Information And Sales Area

Table 52: Medicago. Products Portfolio

Table 53: Novavax Basic Information And Sales Area

Table 54: Novavax. Products Portfolio

Table 55: Saiba Animal Health Basic Information And Sales Area

Table 56: Saiba Animal Health. Products Portfolio

Table 57: VBI Basic Information And Sales Area

Table 58: VBI. Products Portfolio

Table 59: ARTES Biotechnology Basic Information And Sales Area

Table 60: ARTES Biotechnology. Products Portfolio

Table 61: VLP Therapeutics Basic Information And Sales Area

Table 62: VLP Therapeutics. Products Portfolio

Table 63: POSVAX Basic Information And Sales Area

Table 64: POSVAX. Products Portfolio

Table 65: Spybiotech Basic Information And Sales Area

Table 66: Spybiotech. Products Portfolio

Table 67: Optipharm Co. Ltd Basic Information And Sales Area

Table 68: Optipharm Co. Ltd. Products Portfolio

Table 69: H&Z Life Science Basic Information And Sales Area

Table 70: H&Z Life Science. Products Portfolio

Table 71: Gproan Basic Information And Sales Area

Table 72: Gproan. Products Portfolio

Table 73: Merck Basic Information And Sales Area

Table 74: Merck. Products Portfolio

Table 75: Global Market Value (USD Million) (2025-2032) By Application

Table 76: Global Market Share (%) By Application (2032)

Table 77: Global Market Value (USD Million) (2025-2032) By Types

Table 78: Global Market Share (%) By Types (2032)

Table 79: Global Market Volume (K) (2025-2032) By Application

Table 80: Global Market Share (%) By Application (2032)

Table 81: Global Market Volume (K) (2025-2032) By Types

Table 82: Global Market Share (%) By Types (2032)

Table 83: Global vlp vaccines Market Value (USD Million) By Region

Table 84: Global vlp vaccines Market Share (%) By Region (2025-2032)

Table 85: North America Market Value (USD Million) (2025-2032) By Country

Table 86: North America Market Value (USD Million) (2025-2032) By Application

Table 87: North America Market Value (USD Million) (2025-2032) By Types

Table 88: Europe Market Value (USD Million) (2025-2032) By Country

Table 89: Europe Market Value (USD Million) (2025-2032) By Application

Table 90: Europe Market Value (USD Million) (2025-2032) By Types

Table 91: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 92: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 93: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 94: South America Market Value (USD Million) (2025-2032) By Country

Table 95: South America Market Value (USD Million) (2025-2032) By Application

Table 96: South America Market Value (USD Million) (2025-2032) By Types

Table 97: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 98: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 99: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 100: Global vlp vaccines Market Volume (K) By Region

Table 101: Global vlp vaccines Market Share (%) By Region (2025-2032)

Table 102: North America Market Volume (K) (2025-2032) By Country

Table 103: North America Market Volume (K) (2025-2032) By Application

Table 104: North America Market Volume (K) (2025-2032) By Types

Table 105: Europe Market Volume (K) (2025-2032) By Country

Table 106: Europe Market Volume (K) (2025-2032) By Application

Table 107: Europe Market Volume (K) (2025-2032) By Types

Table 108: Asia Pacific Market Volume (K) (2025-2032) By Country

Table 109: Asia Pacific Market Volume (K) (2025-2032) By Application

Table 110: Asia Pacific Market Volume (K) (2025-2032) By Types

Table 111: South America Market Volume (K) (2025-2032) By Country

Table 112: South America Market Volume (K) (2025-2032) By Application

Table 113: South America Market Volume (K) (2025-2032) By Types

Table 114: Middle East & Africa Market Volume (K) (2025-2032) By Country

Table 115: Middle East & Africa Market Volume (K) (2025-2032) By Application

Table 116: Middle East & Africa Market Volume (K) (2025-2032) By Types

Table 117: Research Programs/Design For This Report

Table 118: Key Data Information From Secondary Sources

Table 119: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

vlp vaccines Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	12.80 million
Revenue forecast in 2033	27.84 million
Growth rate	CAGR of 10.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Medicago; Novavax; Saiba Animal Health; VBI; ARTES Biotechnology; VLP Therapeutics; POSVAX; Spybiotech; Optipharm Co. Ltd; H&Z Life Science; Gproan; Merck
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options